PEDIATRICS Vol. 96 No. 6 December 1995, pp. 1057-1061
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Durongpisitkul, K.
Right arrow Articles by Martin, C. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Durongpisitkul, K.
Right arrow Articles by Martin, C. F.

The Prevention of Coronary Artery Aneurysm in Kawasaki Disease: A Meta-analysis on the Efficacy of Aspirin and Immunoglobulin Treatment

Kritvikrom Durongpisitkul MD1, Vymutt J. Gururaj MD1, Joon M. Park MD1, and Clyde F. Martin PhD2

1 Department of Pediatrics, Texas Tech University Health Sciences Center, School of Medicine, Lubbock
2 Department of Preventive Medicine, Texas Tech University Health Sciences Center, School of Medicine, Lubbock

Objective. Varying observations have been made concerning the use of aspirin (ASA) and/or intravenous immunoglobulin (IVIG) in the prevention of coronary artery aneurysm (CAA) in children with Kawasaki disease. A meta-analysis of published articles on the subject was conducted to evaluate the reported efficacy of these therapies.

Methods. All published studies in all languages from 1967 through 1993 obtained from MEDLINE and EMBASE were considered, and a defined set of inclusion and exclusion criteria selected the studies for analysis. These studies were grouped based on whether the children in the studies received: (1) ASA alone, (2) low IVIG (le1 g/kg) and ASA, (3) high IVIG (>1 g/kg) and ASA, (4) single IVIG (>1 g/kg) and ASA, (5) high IVIG and low ASA (le80 mg/kg), or (6) high IVIG and high ASA (> 80mg/kg). Studies that satisfied the test for homogeneity were subjected to further analysis. The best estimate of the true proportion of CAA as well as the 95% confidence interval for each group were calculated at 30 and 60 days. Hypothesis testing was conducted to determine the statistical significance of the calculated difference in each compared treatment group.

Results. The best estimate of true proportion of CAA and the 95% confidence interval in each group at 30 and 60 days were: (1) ASA group, 30 days, 22.8% (20.6%, 25%); 60 days, 17.1% (13.6%, 20.7%); (2) low-IVIG group, 30 days, 17.3% (14.3%, 20.2%); 60 days, 11.1% (8.7%, 13.6%); (3) high-IVIG group, 30 days, 10.3% (8.3%, 12.3%); 60 days, 4.4% (2.8%, 6%); (4) single-IVIG group, 30 days, 2.3% (0.5%, 4.2%); 60 days, 2.4% (0.5%, 4.2%); (5) high-IVIG-low-ASA group, 30 days, 13% (9%, 17%); 60 days, 4.8% (2.3%, 7.4%); and (6) high-IVIG-high-ASA group, 30 days, 9.1% (6.9%, 11.4%); 60 days, 4% (2%, 6.1%).

Conclusion. The incidence of CAA both at 30 and 60 days was significantly lower in low-IVIG than in ASA and in high-IVIG than in low-IVIG groups. Also, the incidence was lower in the single-IVIG than in the high-IVIG group, but this was noted at 30 days and not at 60 days. There was no statistically significant difference in the incidence of CAA both at 30 and 60 days between the high-IWIG-low-ASA and high-IVIG-high-ASA groups.

Submitted on October 14, 1994
Accepted on December 27, 1994




This article has been cited by other articles:


Home page
 NEJMHome page
J. W. Newburger, L. A. Sleeper, B. W. McCrindle, L. L. Minich, W. Gersony, V. L. Vetter, A. M. Atz, J. S. Li, M. Takahashi, A. L. Baker, et al.
Randomized Trial of Pulsed Corticosteroid Therapy for Primary Treatment of Kawasaki Disease
N. Engl. J. Med., February 15, 2007; 356(7): 663 - 675.
[Abstract] [Full Text] [PDF]

Home page
 J Trop PediatrHome page
S. D'Souza, R. P. Khubchandani, and A. K. Shetty
Kawasaki Disease Presenting with Hemorrhagic Pleural Effusion
J Trop Pediatr, August 1, 2006; 52(4): 299 - 301.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
A. C. Wooditch and S. C. Aronoff
Effect of Initial Corticosteroid Therapy on Coronary Artery Aneurysm Formation in Kawasaki Disease: A Meta-analysis of 862 Children
Pediatrics, October 1, 2005; 116(4): 989 - 995.
[Abstract] [Full Text] [PDF]

Home page
 EDUCATION AND PRACTICEHome page
M Wood, M Abinun, and H Foster
Pyrexia of unknown origin
Arch. Dis. Child. Ed. Pract., December 1, 2004; 89(3): ep63 - ep69.
[Full Text] [PDF]

Home page
 PediatricsHome page
J. W. Newburger, M. Takahashi, M. A. Gerber, M. H. Gewitz, L. Y. Tani, J. C. Burns, S. T. Shulman, A. F. Bolger, P. Ferrieri, R. S. Baltimore, et al.
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association
Pediatrics, December 1, 2004; 114(6): 1708 - 1733.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
K.-S. Hsieh, K.-P. Weng, C.-C. Lin, T.-C. Huang, C.-L. Lee, and S.-M. Huang
Treatment of Acute Kawasaki Disease: Aspirin's Role in the Febrile Stage Revisited
Pediatrics, December 1, 2004; 114(6): e689 - e693.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. W. Newburger, M. Takahashi, M. A. Gerber, M. H. Gewitz, L. Y. Tani, J. C. Burns, S. T. Shulman, A. F. Bolger, P. Ferrieri, R. S. Baltimore, et al.
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association
Circulation, October 26, 2004; 110(17): 2747 - 2771.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
P. Monagle, A. Chan, P. Massicotte, E. Chalmers, and A. D. Michelson
Antithrombotic Therapy in Children*: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 645S - 687S.
[Abstract] [Full Text] [PDF]

Home page
 EDUCATION AND PRACTICEHome page
I. K Maconochie
KAWASAKI DISEASE
Arch. Dis. Child. Ed. Pract., June 1, 2004; 89(1): ep3 - ep8.
[Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
Y Uziel, P J Hashkes, E Kassem, G Gottesman, and B Wolach
"Unresolving pneumonia" as the main manifestation of atypical Kawasaki disease
Arch. Dis. Child., October 1, 2003; 88(10): 940 - 942.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
H. C. Meissner and D. Y. M. Leung
Kawasaki Syndrome: Where Are the Answers?
Pediatrics, September 1, 2003; 112(3): 672 - 676.
[Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
J. Genizi, D. Miron, R. Spiegel, D. Fink, and Y. Horowitz
Kawasaki Disease in Very Young Infants: High Prevalence of Atypical Presentation and Coronary Arteritis
Clinical Pediatrics, April 1, 2003; 42(3): 263 - 267.
[PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
C M Wiles, P Brown, H Chapel, R Guerrini, R A C Hughes, T D Martin, P McCrone, J Newsom-Davis, J Palace, J H Rees, et al.
Intravenous immunoglobulin in neurological disease: a specialist review
J. Neurol. Neurosurg. Psychiatry, April 1, 2002; 72(4): 440 - 448.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
P A Brogan, A Bose, D Burgner, D Shingadia, R Tulloh, C Michie, N Klein, R Booy, M Levin, and M J Dillon
Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research
Arch. Dis. Child., April 1, 2002; 86(4): 286 - 290.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
L. M. Voss, N. J. Wilson, J. M. Neutze, R. M. L. Whitlock, R. V. Ameratunga, L. M. Cairns, and D. R. Lennon
Intravenous Immunoglobulin in Acute Rheumatic Fever : A Randomized Controlled Trial
Circulation, January 23, 2001; 103(3): 401 - 406.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
P. Monagle, A. D. Michelson, E. Bovill, and M. Andrew
Antithrombotic Therapy in Children
Chest, January 1, 2001; 119(1_suppl): 344S - 370S.
[Full Text] [PDF]

Home page
 PediatricsHome page
C. A. Wallace, J. W. French, S. J. Kahn, and D. D. Sherry
Initial Intravenous Gammaglobulin Treatment Failure in Kawasaki Disease
Pediatrics, June 1, 2000; 105(6): 78e - 78.
[Abstract] [Full Text]

Home page
 Vasc MedHome page
J. W Newburger and J. C Burns
Kawasaki disease
Vascular Medicine, August 1, 1999; 4(3): 187 - 202.
[Abstract] [PDF]